NRX Pharmaceuticals, Inc. - NRXP STOCK NEWS

NRx Pharmaceuticals (NRXP) announced its participation in the NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference. Dr. Jonathan Javitt, Chairman, CEO and Chief Scientist, will present on December 3, 2024, at 1:00 PM EST at Florida Atlantic University. A high-definition video webcast will be available the following day on the company's website, Noble Capital Markets' Conference website, and Channelchek platform, where it will remain archived for 90 days.

NRx Pharmaceuticals announced the publication of a paper in the American Journal of Clinical Psychopharmacology highlighting their improved methodology for depression rating quality assurance in clinical trials. The company developed an enhanced training and monitoring program for study site raters that achieved 94.5% concordance with central raters, allowing for a maximum variance of 3 points on a 60-point scale. This improved accuracy enabled their phase 2b/3 clinical trial of NRX-101 to achieve statistical significance with fewer than 100 participants, compared to the several hundred typically required. The methodology demonstrated significant improvements in measuring recovery from suicidality and reduction in akathisia.

NRx Pharmaceuticals (NRXP) has appointed Michael Abrams as permanent Chief Financial Officer, replacing Interim-CFO Richard Narido. Abrams brings nearly three decades of experience as an executive officer, investment banker, and senior advisor, including CFO roles at Arch Therapeutics, RiseIT Solutions, and FitLife Brands. He specializes in financial operations, accounting, M&A, and capital raising. Narido will continue supporting the company's financial function and focus on HOPE Therapeutics projects. The appointment aligns with NRx's goal of transitioning from a pre-revenue biotechnology company to a profitable enterprise.

NRx Pharmaceuticals (NRXP) reported significant progress in Q3 2024, with plans to file NDAs for NRX-100 (IV Ketamine) and NRX-101 for treating suicidal ideation in depression by year-end 2024. The company achieved a 74% reduction in net operating losses compared to Q3 2023, reducing from $6.1M to $1.6M. HOPE Therapeutics, their subsidiary, is acquiring Interventional Psychiatry Clinics and expects first revenue by year-end 2024. The company secured $10.8M in convertible-debt funding and forecasts profitability in 2025 from HOPE Therapeutics and medication sales.

NRx Pharmaceuticals (NASDAQ: NRXP) has rescheduled its third quarter and year to date 2024 financial results conference call to Monday, November 18, 2024, at 4:30 PM ET. The change was made to accommodate potential additional corporate news. Investors can access the conference call through a live webcast on the company's website or via telephone using domestic (+1-800-717-1738) or international (+1-646-307-1865) dial-in numbers.

NRx Pharmaceuticals (NASDAQ: NRXP) announced it will release its third quarter and year to date 2024 financial results after market close on Thursday, November 14, 2024. The company will host a conference call at 4:30 PM ET on the same day to discuss the results and provide a corporate update. The conference call will be accessible via webcast on the company's website and through telephone dial-in options for both domestic (+1-800-717-1738) and international (+1-646-307-1865) participants.

HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals (Nasdaq: NRXP), has signed a non-binding Letter of Intent to acquire Interventional Psychiatry Clinics in Florida. The target clinics are described as top performers, currently generating revenue and positive EBITDA. The acquisition is expected to be immediately accretive to both revenue and EBITDA for HOPE and NRx. These facilities will serve as the foundation for HOPE's expansion in Florida, offering comprehensive mental health services. The company aims to establish HOPE as a model for clinics providing the latest standard of care treatments for CNS healthcare providers nationwide.

NRx Pharmaceuticals (NRXP) and its wholly-owned subsidiary HOPE Therapeutics announced their participation in the upcoming ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. Dr. Jonathan Javitt, Chairman and Chief Scientist of NRx and Co-CEO of Hope, will present at 8:30 AM ET. The conference brings together institutional investors, corporate clients, and industry professionals. The NRx management team will conduct one-on-one investor meetings throughout the day. The presentation will be available via live stream on the NRx Events platform.

HOPE Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), has announced signing a non-binding Letter of Intent (LOI) to acquire a premier West Coast Interventional Psychiatric Clinic. This acquisition is set to establish HOPE's model for a network of clinics across the country, providing advanced treatments for CNS disorders such as suicidal depression and PTSD.

Key points of the announcement include:

• The clinic's founder, a nationally recognized leader in advanced CNS disorder treatments, will join HOPE as Chief Medical Innovation Officer (CMIO).
• The acquisition is expected to be immediately accretive to revenue and EBITDA for both HOPE and NRx.
• The clinic will serve as a prototype for HOPE's network, offering treatments like Ketamine, Spravato, Transcranial Magnetic Stimulation (TMS), and talk therapy.
• Patients may also gain access to clinical trials of new treatment modalities through these clinics.